Where we end up is important not the upfront.
We didn't wait all these years and kept faith for 200-300m valuation, let's be serious guys.
A licensing agreement is a reflection of trust in science by other Pharma company who have made a decision to partner after a full on due diligence and know way more about science than any of us.
I am really interested to see the deal structure as I won't be surprised to see Dimerix trading around 1bn post March results (assuming it's positive and it's a global agreement).
Where we end up is important not the upfront. We didn't...
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 37.0¢ | $472.6K | 1.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 152623 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 112709 | 8 |
View Market Depth
| Last trade - 14.34pm 27/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |